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Background: Worldwide, type 2 diabetes (T2DM) prevalence has more than doubled over two decades. In
Australia, diabetes is the second highest contributor to the burden of disease. Lifestyle modification programs
comprising diet changes, weight loss and moderate physical activity, have been proven to reduce the incidence of
T2DM in high risk individuals.
As part of the Council of Australia Governments, the State of Victoria committed to develop and support the
diabetes prevention program ‘Life! Taking action on diabetes’ (Life!) which has direct lineage from effective clinical
and implementation trials from Finland and Australia. The Melbourne Diabetes Prevention Study (MDPS) has been
set up to evaluate the effectiveness and cost-effectiveness of a specific version of the Life! program.
Methods/design: We intend to recruit 796 participants for this open randomized clinical trial; 398 will be allocated
to the intervention arm and 398 to the usual care arm. Several methods of recruitment will be used in order to
maximize the number of participants. Individuals aged 50 to 75 years will be screened with a risk tool (AUSDRISK)
to detect those at high risk of developing T2DM. Those with existing diabetes will be excluded. Intervention
participants will undergo anthropometric and laboratory tests, and comprehensive surveys at baseline, following
the fourth group session (approximately three months after the commencement of the intervention) and
12 months after commencement of the intervention, while control participants will undergo testing at baseline and
12 months only.
The intervention consists of an initial individual session followed by a series of five structured-group sessions. The
first four group sessions will be carried out at two week intervals and the fifth session will occur eight months after
the first group session. The intervention is based on the Health Action Process Approach (HAPA) model and
sessions will empower and enable the participants to follow the five goals of the Life! program.
Discussion: This study will determine whether the effect of this intervention is larger than the effect of usual care
in reducing central obesity and cardiovascular risk factors and thus the risk of developing diabetes and
cardiovascular disease. Also it will evaluate how these two options compare economically.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12609000507280
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The dramatic increase in the prevalence of type 2 dia-
betes (T2DM) is posing a major international health
problem [1] and there is an urgent need to implement a
widespread and coordinated approach to its prevention.
Worldwide, T2DM prevalence has more than doubled
since 1981 and the total number of cases was almost
347 million adults in 2010 [2]. Currently in Australia,
diabetes is the second highest contributor to the burden
of disease, responsible for 5.2% of disability adjusted life-
years (DALYs), and by 2023 it will be the leading cause,
responsible for 8.6% of the overall disease burden [3].
Diabetes also poses an enormous economic burden,
accounting for AU$1.4 billion in 2003 and projected to
increase to almost AU$7 billion by 2033 [4].
Several recent clinical trials conducted on individuals
have demonstrated that lifestyle modification with weight
loss and moderate exercise can reduce the incidence of
T2DM in high risk individuals by up to 58% [5-7]. Life-
style modification has been shown to be even more effec-
tive than drug treatment using metformin or rosiglitazone
[5,8] and seems to have an impact lasting at least several
years following the active intervention [9-11]. The chal-
lenge is to implement the outcomes of these studies in the
‘real world’ of financially constrained health services.
In 2004 to 2006, the Australian Government funded a
group-based lifestyle modification implementation trial -
the Greater Green Triangle Diabetes Prevention Project
(GGT DPP) - to determine its efficacy and feasibility in
primary care [12]. From changes in waist circumference,
it is imputed that this program reduced participants’
projected risk of diabetes by 40%, cardiovascular disease
(CVD) by 16%. GGT DPP was derived from the Finnish
Diabetes Prevention Study (DPS) clinical trial [13] and a
sister project to the Good Ageing in Lahti Region
(GOAL) Lifestyle Implementation Trial in Finland [14].
Life! taking action on diabetes (Life!)
In Australia, the Federal and State Governments colla-
borate through the Council of Australian Governments
(COAG). In health, diabetes prevention is considered one
of the top priority areas. In 2007, as part of the COAG
initiative for diabetes, the Victorian State Government
committed AU$18.3 million of funding over four years for
25,000 high-risk individuals over 50 years old to partici-
pate in a diabetes prevention program called ‘Life! Taking
action on diabetes’ (Life!) to be conducted by Diabetes
Australia Victoria (DA Vic). Life! is a group based lifestyle
change program and has direct lineage from the DPS,
GOAL, and GGT DPP and its goals are described below.
The first Life! participants started the six session pro-
gram in April 2008. At the start of June 2012, 13,946
people had commenced a Life! group course. In 2010, the
Life! program underwent some changes to the entryrequirements and intervention structure. The program will
continue to evolve over time. In May 2011, the Victorian
State Government announced continued funding for Life!
for a further four years with an added emphasis on CVD
prevention. The Life! program was originally accessible for
individuals 50 years old and over with good English profi-
ciency and at high risk of developing diabetes.
The goals of the Life! program were developed based
on the experiences reported by two clinical trials of pre-
vention of T2DM with life-style modification [5,6]. The
intervention goals are: (1) no more than 30% energy
from fat; (2) no more than 10% energy from saturated
fat; (3) at least 15 g/1,000 kcal fiber intake; (4) at least
30 minutes/day moderate intensity physical activity; and
(5) at least 5% reduction in body weight. Participants in-
dividually tailor and modify the goals over the course of
the sessions.
The Melbourne diabetes prevention study (MDPS)
The Melbourne Diabetes Prevention Study (MDPS) is a
research project set up to study in detail a cohort of
individuals undertaking the Life! program in order to
evaluate the effectiveness of a large-scale prevention pro-
gram and, importantly, the cost-effectiveness. The focus
of the present study is a specific modification of the pro-
gram developed in 2011. The program to be evaluated
consists of an individual session and five group sessions
(‘1+5 model’) as presented further below.
The working hypotheses of the MDPS are that (1) the
MDPS program results in statistically and clinically
significant changes (relative to usual care) in clinical,
behavioral, and patient relevant outcomes, particularly
changes in weight and waist circumference, that reduce
the risk of progression to T2DM; and (2) the diabetes
prevention program provided in this study is both ‘cost-
effective’ (relative to usual care using a yardstick of
$50,000 per quality adjusted life year (QALY)) and
performs well in the second stage filter implementation
analysis (the protocol for the economic appraisal will be
presented separately).
Methods/design
Study design
The MDPS is a prospective, open, randomized controlled
trial to assess the effectiveness and cost-effectiveness of a
structured diabetes prevention program implemented in
Victoria for people 50- to 75-years old who are at high risk
of developing T2DM. This is a parallel group study, with
the intervention group receiving a diabetes prevention
program for 12 months and the control group receiving
usual care from their General Practitioners (GPs) during
the same time period. Intervention participants will un-
dergo anthropometric and laboratory tests, and compre-
hensive surveys at baseline, following the fourth group
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ment of the intervention) and 12 months after commence-
ment of the intervention, while control participants will
undergo testing at baseline and 12 months only.
The study is coordinated from the Melbourne metropo-
litan campus of Deakin University (Victoria, Australia) and
is supported by the National Health and Medical Research
Council of Australia (NH&MRC). Ethical approval was
obtained from the Deakin University Human Research
Ethics Committee (EC66-2009). Written informed consent
will be obtained from all participants.
MDPS uses the existing infrastructure and accredited
Life! providers set in place by DAVic. Deakin University is
one of the accredited Life! providers. Life! facilitators will
undergo additional training because the MDPS interven-
tion is a ‘1+5 model’ version of the Life! program.
Participants
The study population is comprised of individuals 50- to
75-years old, living in the Melbourne metropolitan area,
who are at risk of developing diabetes, but currently do
not have diabetes.
Recruitment processes
Participants are recruited as described below from general
practices, by accredited Life! facilitators, in pharmacies,
and also at local community events within the study
catchment. The project coordinator provides recruiters
with specific training to ensure standardized recruitment
procedures.
1) Recruitment through general practices
Patients 50- to 75-years old are invited to complete
the Australian Diabetes Risk Assessment tool
(AUSDRISK). Those who score 15 or more are
referred to the study by their General Practitioner or
Practice Nurse.
2) Recruitment through accredited Life! providers
A Life! provider is an organization accredited to deliver
the Life! program. These organizations and DAVic
have the opportunity to refer individuals into MDPS.
3) Recruitment through pharmacies
MDPS project pharmacists and research assistants
visit pharmacies and target screening to patients
50-years old and older who have easily-identifiable
characteristics (such as high body mass index or
blood pressure) that are suggestive of higher risk of
T2DM. The questionnaire is completed in the
pharmacy along with the individual’s details.
4) Recruitment through community organization or event
Recruitment also takes place in community settings
such as health clubs/gymnasiums, local chapters of
community service organizations (for example, Rotary,
Lions Club and so on) and community fetes and expos.Eligibility
Individuals 50-to 75-years old are asked to complete an
AUSDRISK test [15] that identifies individuals at high
risk of developing T2DM within five years. Approxi-
mately one person in every seven with a score over 15
will develop diabetes within five years. The ten-item self-
report AUSDRISK test is comparable with the Finnish
Diabetes Risk Score (FINDRISC) tool [16], but includes
ethnicity and country of birth appropriate for the multi-
cultural Australian population.
The procedure for screening, eligibility and recruit-
ment can be viewed in Figure 1. A score of 15 or more
on the AUSDRISK test [17] is the primary inclusion cri-
terion. If the score is 15 or above, the MDPS team mem-
ber will assess the eligibility of the individual by
checking the exclusion criteria, which for both males
and females are (1) already on treatment for type 1 or
type 2 diabetes; (2) laboratory evidence of existing
T2DM defined as having a two-hour oral glucose toler-
ance test (OGTT) result of greater than or equal to 11.1
mmol/L and/or a fasting blood glucose greater than or
equal to 7 mmol/L; (3) cancer (not in remission); (4)
severe mental illness; (5) substance abuse; (6) myocar-
dial infarction in the last three months; (7) pregnancy;
(8) difficulty with English and (9) other household
members involved in the study.
Consent
The MDPS project coordinator contacts eligible parti-
cipants to discuss the study, confirm eligibility criteria and
arrange baseline testing. Eligible individuals recruited
through the above strategies are provided with a plain lan-
guage statement and consent form approved by the Ethics
Committee at the time of recruitment.
Intervention
The MDPS intervention consists of an initial individual
session followed by a series of five structured group ses-
sions. The initial individual session forms a specific design
component of the intervention to maximize participant
retention and increase their personal risk awareness. The
delivery of an individual session runs in accordance with
trials that have indicated that lifestyle interventions that
incorporate individual feedback and goal setting foster a
greater sense of participant engagement, motivation and
ability to maintain lifestyle changes in the long term [11].
The individual session will be 30 to 45 minutes in du-
ration, involving the participant and the facilitator only,
and encompassing risk perception, goal setting, and mo-
tivation to change.
Four group sessions are provided at two week intervals.
A fifth and final group session occurs eight months after
the first group session. All sessions are led by a trained
Life! facilitator, with generally 8 to 15 participants in each
T3S5
IS
Intervention
T2T1
0 8 3 12 months
S1   S2   S3   S4
T1 T3
Usual Care
Figure 2 Structure of the MDPS Group Program.
IS: Individual session.
S1-S5: group sessions.
T1, T2, T3: anthropometric and laboratory tests.
Assessed for eligibility
Includes anyone who completed an AUSDRISK 
at the GP, with a Life! provider, in the 
 pharmacy or at a community event.  
Ineligible
Analysed  
Excluded from analysis 
Lost to follow-up 
Discontinued 
Allocated to intervention
Received allocated intervention
Lost to follow-up 
Discontinued 
Allocated to usual care
Received allocated control
Analysed
Excluded from analysis 
Analysis
Follow-Up
Not interested 
Consented 
Eligible
Ineligible: diagnosis of diabetes
on OGTT
Data Collection 
Randomization
Eligible 
Figure 1 Flow chart of the MDPS.
Davis-Lameloise et al. Trials 2013, 14:31 Page 4 of 9
http://www.trialsjournal.com/content/14/1/31
Davis-Lameloise et al. Trials 2013, 14:31 Page 5 of 9
http://www.trialsjournal.com/content/14/1/31group. The duration of each group session is approxi-
mately 1.5 hours. The control group continues with usual
care as provided by their GP. They may be offered a dia-
betes prevention program at the end of the study.
The intervention and data collection time points for
both intervention and usual care groups are shown in
Figure 2.
The theoretical framework of this intervention is based
on the Health Action Process Approach (HAPA) model
and self-regulation theory [18-20]. Several other theories,
strategies and constructs are incorporated into the
design of the intervention. These include the social
learning theory, the trans-theoretical theory of stages
of change [21,22], empowerment-oriented counseling
[23-25], goal-setting approach [26,27], self-efficacy and
self-evaluation [18,28].
The group sessions follow the structure of the HAPA
model. Each session is structured with a major emphasis
on creating an interactive and socially-supportive atmos-
phere. In these sessions the facilitator enables goal
setting, moderates the discussion and feedback, and
strengthens the role of the group as a source of social
support. In addition, individual feedback is provided
to participants from anthropometric and laboratory
measurements at the second clinical testing session
(which follows the fourth group session - approximately
three months after the commencement of the interven-
tion). This individual feedback is used to evaluate the
impact of the intervention and to sustain participants’
motivation in their lifestyle changes.
Outcome assessments
Primary outcomes
The primary outcomes under investigation are changes
in diabetes and CVD risk as determined by changes
in weight, waist circumference, fasting plasma and
two-hour glucose, blood pressure and lipids. These are
determined through anthropometric and laboratory
measurements (performed as detailed below) at baseline,
following the fourth group session (approximately three
months after the commencement of the intervention)
and 12 months after commencement of the intervention.
The reduction in diabetes risk is calculated from the
reduction in weight and waist circumference [12] and
the reduction in cardiovascular risk from changes to the
Framingham risk score, which incorporates the changes
in the individual risk factors.
Secondary outcomes
Changes in psychosocial and quality of life measurements
(performed as detailed below) are the secondary outcomes.
There is also an economic assessment of the program
(separate protocol) by evaluating: whether it is ‘value for
money’ through Cost Utility Analysis (CUA), evaluatingtechnical efficiency issues through Cost Effectiveness
Analysis (CEA) and by assessing a broader range of
factors to supplement the technical analysis, based on
second stage filter implementation analysis pioneered in
Assessing Cost-Effectiveness (ACE) projects [29]. The
final aim is to evaluate the ‘usual care’ of individuals at
high risk of progression to T2DM.Anthropometric measurements and laboratory testing
Study nurses are specifically trained to undertake stan-
dardized anthropometric measurements including height,
weight, waist and hip circumferences, and blood pressure.
These measurements and the laboratory procedures fol
low the international recommendations: the World Health
Organization’s Multinational Monitoring of Trends and
Determinants in Cardiovascular Disease (MONICA) Proto-
col [30] and the latest recommendations of the European
Health Risk Monitoring protocol [31]. All measurements
are recorded on the Clinical Test Form and are performed
at baseline, following the fourth group session (approxi-
mately three months after the commencement of the in-
tervention) and 12 months after commencement of the
intervention for the intervention group and only at baseline
and 12 months for the control group.Anthropometric measurements
Height is measured at baseline and confirmed at sub-
sequent testing using a portable height stadiometer
(Charder). Participants are asked to remove their shoes
and any hair ornaments. Height is recorded to the reso-
lution of the height rule (1 mm).
Weight is measured with a weight scale (Charder
MS3200) placed on a hard surface. The scale is tested in
order to check that it gives a zero value. Participants are
asked to remove their heavy outer garments and shoes,
empty their pockets and remove heavy belts and items.
The participant stands in the center of the platform, with
weight evenly distributed between both feet. Weight is
recorded to the resolution of the scale (0.1 kg).
The waist circumference is measured with a measuring
tape (Seca203). The length of the tape is checked every
month against the height rule. If the measuring tape is
stretched it is replaced. Waist circumference is measured
at a level midway between the lower rib margin and the
iliac crest with a tape around the body in a horizontal
position. Participants are asked to remove their clothes,
except for light underwear. Measurements are recorded
twice according to the resolution of the tape (1 mm) and
the mean is used for data analysis.
Hip circumference is measured as the maximal cir-
cumference over the buttocks. The measurement pro-
cedure is the same as for the waist measurement with
the exception of the tape position.
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momanometer (Omron HEM-907). Blood pressure will
be measured in the sitting position after at least five
minutes rest. The measurement is taken from the bare
right upper arm. The arm should be resting on the desk
so that the antecubital fossa is level with the heart and
the palm of the hand is facing up. The cuff should be
placed on the right arm and its bottom edge should be
2 to 3 cm above the antecubital fossa. The top edge of
the cuff should not be restricted by clothing. Two
measurements are taken one minute apart and the mean
is used for data analysis. If the second measurement
differs by more than 10 mmHg systolic or 6 mmHg dia-
stolic, a third measurement is taken one minute later.
The mean of the closest two systolic and diastolic mea-
surements is used for analysis.
Laboratory measurements
Participants are asked to fast from 10 pm the night prior
to their appointment and samples are drawn for fasting
plasma glucose (FPG), HbA1c and lipid profile at baseline,
following the fourth group session (approximately three
months after the commencement of the intervention) and
12 months after commencement of the intervention and
only at baseline and twelve months for the control group.
Compliance with fasting is recorded before each clinical
test by asking participants the duration of their fasting
period. A two-hour OGTT follows in which the partici-
pant ingests a 75 g glucose solution. Two hours after this
a further blood sample for glucose is taken. The time of
the glucose ingestion and second blood withdrawal are
recorded. The OGTT is performed at baseline and 12
months for both intervention and control arms.
The baseline results from the FPG and two-hour OGTT
determine the final eligibility. If diabetes is diagnosed
(FPG greater than or equal to 7 mmol/L and/or two-hour
glucose greater than or equal to 11.1 mmol/L), the individ-
ual will be referred to their GP and will not be eligible to
enter the study.
All patients who complete the clinical testing receive a
letter documenting their results, with standardized feed-
back. A copy is also sent to their nominated GP. If dia-
betes is diagnosed, an individual covering letter is sent
to the participant referring them back to their GP for
suitable treatment.
Additional blood from consenting participants will be
drawn and bio-banked at −70°C (ULT REVCO 1786) for
further possible biochemical analysis.
Psychosocial and quality of life measurements
Self-reported questionnaires are given to participants at
baseline, following the fourth group session (approxi-
mately three months after the commencement of the
intervention) and 12 months after commencement ofthe intervention. Health status questions include demo-
graphics, smoking status, history of diabetes, myocardial
infarction, cancer and mental disorders. Self-regulation
[32], self-efficacy specified for diet and physical activity
[18,19,33,34], risk perception for diabetes, lifestyle plan-
ning, social support [35], and quality of life (AQoL8D)
[36] are assessed. The Hospital Anxiety and Depression
Scale (HADS) [37], the health related hardiness [38] and
a physical activity assessment (Active Australia) [39] are
also part of this questionnaire. Food Frequency Ques-
tionnaires (FFQ) [40] are completed at baseline and 12
months. Participants are also asked to complete a ques-
tionnaire related to the evaluation of the MDPS inter-
vention at the 12 month clinical test.
If a participant scores 11 or more on the HADS tool
for anxiety and/or depression at any of the testing
sessions, an individual covering letter is sent to the par-
ticipant referring them back to their GP for suitable
treatment.
Sample size and power calculation
For the estimation of sample size for two groups, with a
two-sided 5% significance level and 80% power, the total
number required will be 598 (299 in each arm). The
sample size calculation was based on the observed mean
change in diastolic blood pressure, a CVD risk factor, in
the GGT-DPP and powered to detect an effect size of at
least 0.23. To allow for an estimated attrition of up to 25%
(estimate based on the GGT DPP), we require a total sam-
ple of 796 (398 in each arm). This sample size will provide
sufficient power for other CVD risk factors, such as total
and high-density lipoprotein (HDL)-cholesterol, as well as
diabetes risk factors including fasting plasma glucose,
weight, and waist circumference, as these are all expected
to have larger effect sizes.
Randomization
Randomization to either the intervention or usual care
arm is made after confirmation of the eligibility of the
patient, and after exclusion of T2DM, based on the base-
line clinical test results (both FPG <7 mmol/L and
OGTT two-hour glucose <11.1 mmol/L). Randomization
is generated by a random number table and participant
instructions are placed in individual sealed, opaque
envelopes. The Project Coordinator selects the next se-
quential envelope to be attributed to a new participant.
A covering letter is sent to participants indicating which
group (Intervention or Control) they are allocated to,
and what the subsequent processes are for participating
in the study.
Data management
Data are entered on two separate password protected
databases: the ‘participant’ database and the ‘intervention’
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participants who have been registered in the trial along
with their personal details, recruitment method, baseline
testing date, allocations, and recall date for testing. This
database is hosted on a secure, virtual server and is access-
ible only by the Project Coordinator, Study Nurse, Facilita-
tor, administrative staff and Senior Program Manager. The
second database, the ‘intervention’ database, contains de-
identified data including blood test results, questionnaires,
and anthropometrics. Data collected from participants at
each testing session (baseline, following the fourth group
session (approximately three months after the commence-
ment of the intervention) and 12 months after com-
mencement of the intervention) are checked for accuracy
and completeness through routine data cleaning and man-
agement procedures.
The establishment of two databases allows manage-
ment of the trial without violation of privacy or con-
fidentiality of participant data and the integrity of
allocation concealment. Only the Project Coordinator
and specified members of the Study Team have access
to identifiable data on a predetermined ‘need-to-know’
basis. The ‘participant’ database supports the regular
generation of reports on those participants due for clini-
cal testing, or completing an intervention.
Data analysis
Analyses will be performed using Stata version 12 or later,
and the ‘intention-to-treat’ principle will be adhered to.
Baseline characteristics will be compared between inter-
vention and control groups using chi-square tests, inde-
pendent t-tests, and the Wilcoxon rank-sum test as
appropriate. Primary and secondary outcomes (as des-
cribed above) will be evaluated using mixed models,
treating ‘group’ as a between-subject factor and ‘time’ as a
within-subject factor. Two-sided tests will be used, with a
level of P <0.05 determining statistical significance.
A separate and parallel economic evaluation protocol
will be described elsewhere.
Discussion
This study is necessary because it is important to know if
this specific modification of the Life! diabetes prevention
program leads to a reduction in diabetes risk, whether this
reduction is larger than the effect of usual care and how
these two options compare economically. Information
about the characteristics of participants that predict com-
pletion of the program and improvement in clinical and
behavioral measures will be useful for further develop-
ment of diabetes prevention programs. Translating clinical
trials into effective population programs is very challen-
ging, but this translational process can be successful. We
expect that MDPS will confirm the effectiveness of Life!
and may allow us to refine it further.The links to health policy are immediate: the COAG has
on its agenda the prevention of progression to diabetes
among those at high risk. The results of this study, inclu-
ding economic evaluation information, will inform policy
and future guidelines and will complement the European
recommendations for prevention of T2DM [41,42].
Trial status
Recruitment of the participants started in September
2011. By 15 November 2012, 2,143 individuals had been
assessed for eligibility and 266 had been randomized.
Twenty-five individuals who completed baseline testing
were found to have met T2D diagnostic criteria and were
excluded from the study. It is anticipated that recruitment
of participants will be end in February 2013.
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